Neuronetics Inc
STIM1.400USD
-0.015-1.06%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
95.82MMarket Cap
LossP/E TTM
More Details of Neuronetics Inc Company
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Neuronetics Inc Info
Ticker SymbolSTIM
Company nameNeuronetics Inc
IPO dateJun 28, 2018
CEOMr. Keith J. Sullivan
Number of employees716
Security typeOrdinary Share
Fiscal year-endJun 28
Address3222 Phoenixville Pike
CityMALVERN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19355
Phone18776007555
Websitehttps://neurostar.com/neuronetics/
Ticker SymbolSTIM
IPO dateJun 28, 2018
CEOMr. Keith J. Sullivan
Company Executives of Neuronetics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
+0.32%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
+1.82%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
400.00K
--
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
335.45K
+2.30%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
185.35K
+4.12%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+27.05%
Mr. W. Andrew Macan
Mr. W. Andrew Macan
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Avinash N. Amin, M.D.
Dr. Avinash N. Amin, M.D.
Director
Director
--
--
Mr. Mark Klausner
Mr. Mark Klausner
Managing Partner
Managing Partner
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
+0.32%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
+1.82%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
400.00K
--
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
335.45K
+2.30%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
185.35K
+4.12%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+27.05%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Clinic revenue
23.02M
60.42%
Treatment sessions
11.05M
29.00%
NeuroStar Advanced Therapy System
3.65M
9.57%
Other
385.00K
1.01%
By RegionUSD
Name
Revenue
Proportion
United States
37.66M
98.81%
International
452.00K
1.19%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Clinic revenue
23.02M
60.42%
Treatment sessions
11.05M
29.00%
NeuroStar Advanced Therapy System
3.65M
9.57%
Other
385.00K
1.01%
Shareholding Stats
Updated: Wed, Nov 26
Updated: Wed, Nov 26
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Madryn Asset Management, LP
30.28%
Chernett (Jorey)
6.43%
The Vanguard Group, Inc.
4.14%
UBS Financial Services, Inc.
3.16%
BlackRock Institutional Trust Company, N.A.
3.10%
Other
52.90%
Shareholders
Shareholders
Proportion
Madryn Asset Management, LP
30.28%
Chernett (Jorey)
6.43%
The Vanguard Group, Inc.
4.14%
UBS Financial Services, Inc.
3.16%
BlackRock Institutional Trust Company, N.A.
3.10%
Other
52.90%
Shareholder Types
Shareholders
Proportion
Private Equity
30.28%
Individual Investor
15.58%
Investment Advisor
13.62%
Hedge Fund
9.59%
Investment Advisor/Hedge Fund
6.10%
Research Firm
1.71%
Bank and Trust
0.11%
Pension Fund
0.05%
Venture Capital
0.04%
Other
22.92%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
198
39.45M
57.60%
-13.65M
2025Q2
187
47.56M
71.93%
-4.03M
2025Q1
191
47.19M
71.70%
-4.84M
2024Q4
155
36.70M
70.38%
+11.74M
2024Q3
153
14.58M
47.42%
-9.85M
2024Q2
159
20.22M
66.61%
-5.87M
2024Q1
183
20.38M
68.24%
-3.49M
2023Q4
191
18.37M
63.28%
-7.87M
2023Q3
201
19.69M
68.24%
-8.69M
2023Q2
222
21.10M
73.37%
-11.20M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Madryn Asset Management, LP
20.74M
31.36%
-3.50M
-14.44%
Aug 08, 2025
The Vanguard Group, Inc.
2.74M
4.15%
+436.54K
+18.93%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.05M
3.1%
+1.67M
+440.36%
Jun 30, 2025
Cucuz (Sasha)
2.02M
3.06%
+30.00K
+1.50%
May 22, 2025
Balyasny Asset Management LP
1.51M
2.28%
+92.05K
+6.50%
Jun 30, 2025
Sullivan (Keith J)
1.61M
2.43%
--
--
Mar 24, 2025
Wexford Capital LP
643.07K
0.97%
+171.34K
+36.32%
Jun 30, 2025
Masters Capital Management, L.L.C.
1.00M
1.51%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
3.31%
Invesco NASDAQ Future Gen 200 ETF
0.43%
iShares Neuroscience and Healthcare ETF
0.1%
Vanguard US Momentum Factor ETF
0.04%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.01%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
View more
AdvisorShares Psychedelics ETF
Proportion3.31%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.43%
iShares Neuroscience and Healthcare ETF
Proportion0.1%
Vanguard US Momentum Factor ETF
Proportion0.04%
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Neuronetics Inc?
The top five shareholders of Neuronetics Inc are:
Madryn Asset Management, LP holds 20.74M shares, accounting for 31.36% of the total shares.
The Vanguard Group, Inc. holds 2.74M shares, accounting for 4.15% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.05M shares, accounting for 3.10% of the total shares.
Cucuz (Sasha) holds 2.02M shares, accounting for 3.06% of the total shares.
Balyasny Asset Management LP holds 1.51M shares, accounting for 2.28% of the total shares.
Madryn Asset Management, LP holds 20.74M shares, accounting for 31.36% of the total shares.
The Vanguard Group, Inc. holds 2.74M shares, accounting for 4.15% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.05M shares, accounting for 3.10% of the total shares.
Cucuz (Sasha) holds 2.02M shares, accounting for 3.06% of the total shares.
Balyasny Asset Management LP holds 1.51M shares, accounting for 2.28% of the total shares.
What are the top three shareholder types of Neuronetics Inc?
The top three shareholder types of Neuronetics Inc are:
Madryn Asset Management, LP
Chernett (Jorey)
The Vanguard Group, Inc.
Madryn Asset Management, LP
Chernett (Jorey)
The Vanguard Group, Inc.
How many institutions hold shares of Neuronetics Inc (STIM)?
As of 2025Q3, 198 institutions hold shares of Neuronetics Inc, with a combined market value of approximately 39.45M, accounting for 57.60% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -14.33%.
What is the biggest source of revenue for Neuronetics Inc?
In FY2025Q2, the Clinic revenue business generated the highest revenue for Neuronetics Inc, amounting to 23.02M and accounting for 60.42% of total revenue.
